Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
3
|
pubmed:dateCreated |
1987-4-13
|
pubmed:grant | |
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical | |
pubmed:status |
MEDLINE
|
pubmed:month |
Mar
|
pubmed:issn |
0361-5960
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:volume |
71
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
323-4
|
pubmed:dateRevised |
2007-11-14
|
pubmed:meshHeading |
pubmed-meshheading:3028622-Aclarubicin,
pubmed-meshheading:3028622-Aged,
pubmed-meshheading:3028622-Carcinoma, Non-Small-Cell Lung,
pubmed-meshheading:3028622-Drug Evaluation,
pubmed-meshheading:3028622-Humans,
pubmed-meshheading:3028622-Lung Neoplasms,
pubmed-meshheading:3028622-Middle Aged,
pubmed-meshheading:3028622-Naphthacenes
|
pubmed:year |
1987
|
pubmed:articleTitle |
Phase II study of aclarubicin in non-small cell lung cancer.
|
pubmed:publicationType |
Journal Article,
Research Support, U.S. Gov't, P.H.S.
|